The present work will discuss a case study of the development of the drug VONAU FLASH, focusing on the triple helix model, based on the partnership between the University of São Paulo and the laboratory BIOLAB SANUS FARMACÊUTICA LTDA. The innovation resulted from an objective initiative formulated by the interested company, which allowed the creation of the university's patent and transferred technology to the pharmaceutical company. The commercialization of the developed drug represents 90% of the royalties' revenue from the University of São Paulo, totaling approximately 3,4 million BRL per year. The laboratory projects annual earnings of nearly 165 million BRL per year with the sale of VONAU-FLASH developed with the partnership signed between the University and the company.